

Reference Data

1st Quarter - Fiscal Year 2016
(April 1, 2016 to June 30, 2016)

Consolidated Earnings

• Consolidated Financial Data	P 1
• Consolidated Balance Sheets	P 2
• Consolidated P/L Statement	P 3
• Consolidated Sales Breakdown by Segment/Category	P 4
• Consolidated Operating Income by Segment	P 4
• Consolidated Sales - Leading Brands of Self-Medication Operations	P 5
• Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations	P 6
• Capital Expenditure	P 7
• Depreciation and Amortization	P 7
• R&D Expenses	P 7
• Results of Major Consolidated Subsidiaries	
♦ Taisho Pharmaceutical	P 8
♦ Taisho Toyama Pharmaceutical	P 8
♦ Biofermin Pharmaceutical	P 8
• Major Subsidiaries and Affiliates	P 9
• Prescription Pharmaceutical Operations: New Drug Development-Taisho Pharmaceutical	P10

Consolidated Financial Data

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E(new) (4-9)	2Q E(previous) (4-9)	Full year E
Net sales	69,212	145,984	224,978	290,135	69,431	140,000	140,000	285,000
(YOY%)	(+1.2%)	(+2.9%)	(+1.5%)	(-0.1%)	(+0.3%)	(-4.1%)	(-4.1%)	(-1.8%)
Self-Medication operations	43,602	92,094	138,782	180,722	43,012	91,500	91,500	185,400
Prescription Pharmaceutical operations	25,609	53,889	86,195	109,413	26,418	48,500	48,500	99,600
Gross profit*	42,464	89,106	136,387	176,813	44,409	88,900	88,900	181,500
Selling, general and administrative expenses	37,229	75,180	113,665	147,935	35,302	75,900	77,900	152,000
Research and development expenses	5,406	10,499	15,569	21,768	5,050	11,100	12,200	23,400
(% Sales)	(7.8%)	(7.2%)	(6.9%)	(7.5%)	(7.3%)	(7.9%)	(8.7%)	(8.2%)
Advertising expenses	5,466	11,019	17,849	21,366	5,013	11,300	11,600	23,500
Sales promotion expenses	7,628	15,999	24,615	31,775	7,082	15,300	16,100	30,800
Personnel expenses	9,213	18,241	27,308	36,042	9,090	18,300	18,300	36,700
Operating income	5,234	13,925	22,722	28,878	9,106	13,000	11,000	29,500
(YOY%)	(-39.2%)	(-14.2%)	(-8.5%)	(-9.7%)	(+74.0%)	(-6.6%)	(-21.0%)	(+2.2%)
Ordinary income	7,493	17,680	29,097	36,775	10,422	15,500	14,000	36,500
(YOY%)	(-30.4%)	(-9.7%)	(-5.8%)	(-7.1%)	(+39.1%)	(-12.3%)	(-20.8%)	(-0.7%)
Profit attributable to owners of parent	4,686	11,281	18,705	22,473	6,945	10,000	9,000	24,000
(YOY%)	(-29.6%)	(-10.4%)	(-4.8%)	(-8.4%)	(+48.2%)	(-11.4%)	(-20.2%)	(+6.8%)
Comprehensive income	6,610	7,620	19,940	9,059	3,455	-	-	-
(YOY%)	(-37.3%)	(-58.6%)	(-37.2%)	(-81.1%)	(-47.7%)	-	-	-
Basic EPS (yen)	57.81	139.16	230.74	277.75	86.92	125.15	112.63	300.37
Diluted EPS (yen)	57.78	139.09	230.61	277.59	86.86	125.07	112.56	300.17
BPS (yen)	7,908.88	7,916.70	8,012.47	7,870.04	7,857.63	7,941.28	7,928.77	8,072.90
Dividend per share (yen)	-	50.00	-	100.00	-	50.00	50.00	110.00
Payout ratio	-	-	-	36.0%	-	-	-	36.6%
Capital expenditure	1,057	2,910	5,150	8,967	2,453	5,000	5,000	8,500
Depreciation and amortization	2,716	5,483	8,260	11,117	2,529	5,200	5,200	10,800
Total assets	770,223	768,737	789,243	759,049	751,353	761,000	760,000	771,000
Shareholders' equity	654,801	655,911	664,019	643,127	642,439	649,000	648,000	660,000
Return on equity (%)**	-	-	-	3.5%	-	-	-	3.8%
Return on assets (%)**	-	-	-	2.9%	-	-	-	3.1%
Equity ratio (%)	83.2%	83.5%	82.3%	82.9%	83.6%	83.4%	83.4%	83.7%
Overseas sales	7,720	15,886	22,217	29,901	6,836	14,320	14,320	29,020
Overseas sales ratio (% of total sales)	11.2%	10.9%	9.9%	10.3%	9.9%	10.2%	10.2%	10.2%
Number of employees	6,710	6,637	6,598	6,517	6,596	-	-	-

* After provision/reversal of reserve for returned unsold goods

** Average of the beginning and year-end balance of shareholders' equity / total assets

<Reference>

-E=Estimates

· The 2Q forecasts (previous) for the fiscal year ending March 31, 2017 were announced on May 16, 2016.

Consolidated Balance Sheets

(Millions of yen)

	End of FY2015		End of FY2016/1Q		change	
	(March 31, 16)	% total	(Jun. 30, 16)	% total		
(Assets)						
I Current assets:	319,670	42.1%	316,793	42.2%	-2,876	
Cash and deposits	172,142		175,290		+3,148	
Notes and accounts receivable-trade	75,243		71,703		-3,539	
Marketable securities	34,316		29,230		-5,086	Bond redemptions -5,000
Inventories	26,638		26,712		+73	
Deferred tax assets	6,128		6,411		+282	
Other	5,201		7,444		+2,243	
II Fixed assets:	439,379	57.9%	434,560	57.8%	-4,819	
(1) Tangible fixed assets:	98,950	(13.0%)	99,247	(13.2%)	+297	
Buildings and structures	45,979		45,499		-480	
Machinery, equipment and vehicles	7,211		6,761		-450	
Land	37,473		37,468		-5	
Other	8,285		9,518		+1,233	
(2) Intangible fixed assets:	38,863	(5.1%)	37,692	(5.0%)	-1,171	
Goodwill	19,046		18,577		-468	
Sales rights	4,675		4,360		-314	
Trademarks	12,175		11,694		-481	
Software	2,419		2,512		+93	
Other	547		546		-0	
(3) Investments and other assets:	301,565	(39.7%)	297,619	(39.6%)	-3,945	
Investment securities	237,213		233,691		-3,521	Gain/loss on valuation -3,137
Shares of subsidiaries and affiliates	54,590		54,031		-559	
Net defined benefit assets	568		625		+56	
Deferred tax assets	7,869		7,939		+70	
Other	1,322		1,331		+8	
Total assets	759,049	100.0%	751,353	100.0%	-7,696	

(Liabilities)						
I Current liabilities:	66,646	8.8%	60,827	8.1%	-5,818	
Notes and accounts payable-trade	27,082		23,595		-3,487	
Accounts payable	16,753		14,021		-2,731	
Accrued income tax	5,746		3,535		-2,211	
Provision for bonuses	3,855		2,002		-1,852	
Other	13,207		17,672		+4,464	
II Long-term liabilities:	49,275	6.5%	48,086	6.4%	-1,189	
Net defined benefit liabilities	23,713		23,763		+49	
Deferred taxes liabilities	16,333		15,425		-907	
Other	9,228		8,896		-331	
Total liabilities	115,922	15.3%	108,913	14.5%	-7,008	
(Net assets)						
I Shareholders' equity	600,862	79.2%	603,801	80.4%	+2,939	
Common stock	30,000	4.0%	30,000	4.0%	-	
Capital surplus	15,271	2.0%	15,271	2.0%	+0	
Retained earnings	623,255	82.1%	626,202	83.3%	+2,946	Profit attributable to owners of parent +6,945 Dividend on retained earnings -3,998
Treasury stock	-67,664	-8.9%	-67,672	-9.0%	-7	
II Accumulated other comprehensive income	28,029	3.7%	24,094	3.2%	-3,934	
Valuation difference on securities	35,736	4.7%	33,442	4.5%	-2,293	
Deferred gains or losses on hedges	-0	-0.0%	-2	-0.0%	-1	
Foreign currency translation adjustment	507	0.1%	-1,305	-0.2%	-1,812	
Remeasurements of defined benefit plans	-8,213	-1.1%	-8,039	-1.1%	+173	
III Subscription rights to shares	357	0.0%	349	0.0%	-7	
IV Non-controlling interests	13,878	1.8%	14,193	1.9%	+315	
Total net assets	643,127	84.7%	642,439	85.5%	-687	
Total liabilities and net assets	759,049	100.0%	751,353	100.0%	-7,696	

Consolidated P/L Statement

(Millions of yen)

	FY2015		FY2016		YOY change	
	1Q	% total	1Q	% total		
Net sales	69,212	100.0%	69,431	100.0%	+219	
Cost of sales	26,695	38.6%	25,032	36.1%	-1,663	
Gross profit on sales	42,516	61.4%	44,398	63.9%	+1,882	
Provision for sales returns	52		-10		-62	
Gross profit	42,464	61.4%	44,409	64.0%	+1,944	
Selling, general and administrative expenses	37,229	53.8%	35,302	50.8%	-1,927	
Research and development expenses	5,406		5,050		-355	
Advertising expenses	5,466		5,013		-452	
Sales promotion expenses	7,628		7,082		-545	
Personnel expenses	9,213		9,090		-122	
Other	9,515		9,065		-450	
Operating income	5,234	7.6%	9,106	13.1%	+3,872	
Non-operating income	2,343	3.4%	2,346	3.4%	+3	
Non-operating expenses	84	0.2%	1,031	1.5%	+947	Foreign exchange losses +776 Equity in losses of affiliates +174
Ordinary income	7,493	10.8%	10,422	15.0%	+2,928	
Extraordinary gains	1	0.0%	10	0.0%	+8	
Extraordinary losses	94	0.1%	92	0.1%	-1	
Income before income taxes and minority interests	7,401	10.7%	10,339	14.9%	+2,938	
Income taxes	2,354	3.4%	2,846	4.1%	+492	
Profit	5,047	7.3%	7,492	10.8%	+2,445	
Profit attributable to non-controlling interests	361	0.5%	547	0.8%	+186	
Profit attributable to owners of parent	4,686	6.8%	6,945	10.0%	+2,259	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Self-Medication operations (YOY%)	43,602 (+5.9%)	92,094 (+4.6%)	138,782 (+2.9%)	180,722 (+2.5%)	43,012 (-1.4%)	91,500 (-0.6%)	185,400 (+2.6%)
Japan	35,145	74,717	114,464	148,125	35,560	75,700	153,800
Overseas	7,720	15,880	22,208	29,875	6,832	14,300	29,000
Other	736	1,496	2,108	2,721	620	1,500	2,600
Prescription Pharmaceutical operations (YOY%)	25,609 (-5.8%)	53,889 (+0.3%)	86,195 (-0.7%)	109,413 (-4.2%)	26,418 (+3.2%)	48,500 (-10.0%)	99,600 (-9.0%)
Ethical drugs	24,967	52,740	84,774	107,215	24,562	46,200	96,100
Other	642	1,149	1,421	2,197	1,856	2,300	3,500
Total	69,212	145,984	224,978	290,135	69,431	140,000	285,000

Consolidated Operating Income by Segment

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E(new) (4-9)	2Q E(previous) (4-9)	Full year E
Self-Medication operations (YOY%)	6,067 (-15.1%)	14,530 (-5.0%)	21,103 (-8.3%)	28,393 (-8.6%)	7,022 (+15.7%)	14,500 (-0.2%)	13,300 (-8.5%)	29,600 (+4.2%)
Prescription Pharmaceutical operations (YOY%)	-537 (-)	36 (-97.6%)	2,591 (-4.3%)	1,755 (-15.5%)	2,496 (-)	-800 (-)	-1,600 (-)	1,300 (-26.0%)
Other* (YOY%)	-295 (-)	-641 (-)	-972 (-)	-1,271 (-)	-412 (-)	-700 (-)	-700 (-)	-1,400 (-)
Total	5,234	13,925	22,722	28,878	9,106	13,000	11,000	29,500

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Japan	35.1	74.7	114.5	148.1	35.6	+1.2%	75.7	153.8	+3.8%
Lipovitan series	15.9	33.8	49.0	60.5	15.6	-1.8%	33.6	60.4	-0.2%
Pabron series	4.1	9.9	18.0	24.8	4.3	+4.7%	9.9	25.5	+2.9%
RiUP series	3.6	8.1	12.6	16.5	3.8	+3.3%	7.8	16.9	+1.9%
Livita series	1.0	1.9	2.9	3.9	0.9	-8.5%	1.8	4.0	+2.9%
Gastrointestinal treatment series	0.9	1.9	3.1	4.1	0.9	+5.0%	1.9	4.1	+0.3%
NARON series	0.5	1.4	2.8	3.6	0.5	+2.2%	1.3	3.7	+3.2%
VICKS series	0.9	1.8	2.8	3.7	0.9	-2.1%	1.8	3.6	-2.3%
Colac series	0.8	1.6	2.5	3.3	0.8	+5.6%	1.6	3.4	+0.9%
ZENA series	0.6	1.3	2.1	2.7	0.5	-12.4%	1.5	3.3	+21.7%
Biofermin series	1.8	3.6	5.3	7.5	2.0	+10.9%	4.0	8.2	+10.2%
Overseas	7.7	15.9	22.2	29.9	6.8	-11.5%	14.3	29.0	-2.9%
Energy drinks	2.5	5.4	7.9	10.3	2.5	-0.5%	4.9	9.7	-6.1%
OTC drugs	4.9	10.0	13.6	18.4	4.2	-14.1%	9.1	18.5	+0.6%
Others	0.7	1.5	2.1	2.7	0.6	-15.8%	1.5	2.6	-4.4%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2016(FY2015)				March 2017(FY2016)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Lipovitan series	15.9	33.8	49.0	60.5	15.6	-1.8%	33.6	60.4	-0.2%
Lipovitan D	10.2	21.9	31.6	38.6	10.2	-0.5%	21.7	38.6	-0.1%
Others	5.7	11.8	17.4	21.9	5.4	-4.2%	11.8	21.8	-0.4%
(100mL other Lipovitans)	3.6	7.6	11.0	13.9	3.5	-2.3%	7.7	14.0	+0.7%
(50mL other Lipovitans)	2.1	4.2	6.4	8.0	1.9	-7.6%	4.1	7.8	-2.2%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Brands of Self-Medication Operations

(Billions of Yen)

	March 2015(FY2014)				March 2016(FY2015)					
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E(new) (4-9)	2Q E(previous) (4-9)	Full year E	YOY
Edirol	4.4	9.6	15.2	19.8	5.8	+31.3%	11.1	10.9	22.4	+12.9%
ZOSYN	6.6	14.5	22.8	27.3	4.2	-35.3%	8.3	8.3	15.4	-43.6%
Clarith	2.5	5.2	9.2	12.0	2.2	-10.4%	4.0	4.0	9.8	-18.3%
Bonviva	1.1	2.4	3.7	4.9	1.7	+54.9%	3.1	3.1	6.6	+34.0%
Palux	1.6	3.2	4.9	6.2	1.5	-5.8%	2.6	2.6	5.1	-17.8%
Geninax	0.4	1.1	3.2	4.3	1.1	+178.5%	2.7	2.7	5.0	+16.6%
OZEX	1.4	2.7	4.8	5.9	1.1	-18.2%	2.0	2.0	4.6	-21.6%
Biofermin	0.9	1.7	2.6	3.6	1.0	+18.1%	1.9	1.9	3.8	+6.8%
Lusefi	0.5	0.5	0.7	0.9	0.5	-4.1%	1.0	0.6	2.6	+194.5%
LOQOA	-	-	-	0.4	0.3	-	0.5	0.4	1.8	+312.8%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Total capital expenditure	1,057	2,910	5,150	8,967	2,453	5,000	8,500
Taisho Pharmaceutical	826	2,416	4,174	7,324	2,268	4,000	6,700
Omiya Factory	201	491	682	868	28	480	1,000
Hanyu Factory	0	0	1	21	-	20	60
Okayama Factory	3	5	5	28	0	10	70
Research Center	30	315	381	1,053	134	330	950
Others	590	1,603	3,102	5,351	2,105	3,160	4,620
Other subsidiaries	230	494	976	1,642	185	1,000	1,800

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)		
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E (4-9)	Full year E
Depreciation and amortization	2,716	5,483	8,260	11,117	2,529	5,200	10,800
Cost of sales	947	1,895	2,847	3,823	851	1,800	3,700
SGA expenses	1,768	3,588	5,412	7,293	1,678	3,400	7,100

Consolidated: R&D Expenses

(Millions of yen)

	March 2016(FY2015)				March 2017(FY2016)			
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	2Q E(new) (4-9)	2Q E(previous) (4-9)	Full year E
Total R&D expenses	5,406	10,499	15,569	21,768	5,050	11,100	12,200	23,400
Self-Medication operations	1,210	2,524	3,725	5,497	1,320	2,900	3,300	6,200
Prescription Pharmaceutical operations	4,195	7,975	11,844	16,270	3,730	8,200	8,900	17,200

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2016(FY2015)					
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E(new) (4-9)	2Q E(previous) (4-9)	Full year E	YOY
Net Sales	46.6	98.4	152.5	198.4	49.2	+5.5%	100.9	100.9	207.3	+4.5%
Self-Medication	35.5	75.6	115.7	150.1	35.9	+0.9%	76.7	76.7	155.7	+3.7%
Prescription Pharmaceutical	11.1	22.9	36.8	48.3	13.4	+20.2%	24.2	24.2	51.6	+6.7%
Operating income	2.5	7.9	14.2	19.5	5.9	+137.1%	9.1	7.1	21.4	+9.6%
Ordinary income	5.6	12.2	18.7	24.3	6.6	+18.0%	12.2	10.7	25.6	+5.5%
Profit	4.5	9.5	14.2	17.8	5.2	+16.8%	9.8	8.8	19.7	+10.7%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2016(FY2015)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	25.0	52.7	84.8	107.2	24.6	-1.6%	46.2	96.1	-10.4%
Operating income	0.3	1.3	2.8	2.7	1.4	+307.1%	1.1	2.3	-14.8%
Ordinary income	0.3	1.3	2.8	2.7	1.4	+304.4%	1.1	2.3	-15.0%
Profit	0.1	0.7	1.7	1.4	0.9	+816.7%	0.7	1.5	+6.3%

(Rounded to the nearest hundred-million)

Sales and earnings of Taisho Toyama Pharmaceutical are included in the consolidated results of Prescription Pharmaceutical operations.

Sales and earnings of Biofermin Pharmaceutical

(Billions of Yen)

	March 2016(FY2015)				March 2016(FY2015)				
	1Q (4-6)	2Q (4-9)	3Q (4-12)	Full year	1Q (4-6)	YOY	2Q E (4-9)	Full year E	YOY
Net Sales	2.7	5.4	7.2	9.7	2.6	-4.9%	4.9	10.3	+6.6%
Self-Medication	1.8	3.8	4.9	6.6	1.7	-6.9%	3.3	6.7	+1.7%
Prescription Pharmaceutical	0.8	1.6	2.2	3.1	0.8	-0.6%	1.7	3.6	+17.1%
Operating income	0.9	1.7	1.8	2.3	0.7	-19.0%	1.2	2.4	+3.2%
Ordinary income	0.9	1.7	1.9	2.3	0.8	-19.3%	1.3	2.4	+3.2%
Profit	0.6	1.2	1.3	1.6	0.5	-18.5%	0.9	1.7	+6.9%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of June 30, 2016)

Company	Address	Capital	Business	Ownership
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 29,804,450	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	,000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	,000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	,000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	,000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	,000 Yen 1,227,000	SMG PD	64.0
Taisho Toyama Pharmaceutical Co.,Ltd.	Tokyo, Japan	,000 Yen 2,000,000	PD	70.3
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	,000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	,000 Yen 300,000	SMG PD	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	,000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	,000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	,000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	,000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	,000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	,000 HK\$ 163,000	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	,000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	,000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	,000 rupiah 10,240,000	SMG	98.0
Taisho Pharmaceutical Singapore Private Limited	Singapore	,000 US\$ 1,000	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	,000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	,000 MXN 122,467	SMG	100.0
(2) Equity accounting method				
Toyama Chemical Co.,Ltd.	Tokyo, Japan	,000 Yen 10,000,000	PD	34.0
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	,000 Yen 1,650,000	SMG	24.1

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of August 1, 2016

In Japan

Phase 2

TS-091 (Oral)

- < Application > Central disorders of hypersomnolence
- < Development > In-house

TS-152 (Injection)

- < Application > Rheumatoid arthritis
- < Development > In-license (Licensor: Ablynx)
- < Description > Anti-TNF(Tumor Necrosis Factor)- α antibody
- < Remarks > Generic name: Ozoralizumab

TS-141 (Oral)

- < Application > Childhood Attention-Deficit/Hyperactivity Disorder
- < Development > In-house

Overseas

Phase 1

TS-071 (Oral)

- < Target disease > Type 2 diabetes
- < In-house/Licensed-in > In-house
- < Description > Sodium-glucose cotransporter 2 (SGLT2) inhibitor
- < Remarks > Generic name: Luseogliflozin Hydrate
In Japan: Launched on May 23, 2014 (Product name: Lusefi)

TS-121 (Oral)

- < Target disease > Depression
- < In-house/Licensed-in > In-house

TS-091 (Oral)

- < Target disease > Central disorders of hypersomnolence
- < In-house/Licensed-in > In-house

TS-134 (Oral)

- < Target disease > Schizophrenia
- < In-house/Licensed-in > In-house